Denali Therapeutics Inc. (DNLI)

Nasdaq Biotechnology Diagnostics SIC: 2836
A
Pipeline Grade

Financial Position (from SEC Filings)

$390.7M
Cash & Equivalents
$131.2M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$3,208M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
TIVIDENOFUSP ALFA-EKNM
AVLAYAH 		APPROVED Alzheimer Disease, Alzheimer Disease, Early Onset, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Healthy Participant, Healthy Volunteers, Late-onset Pompe Disease, Mucopolysaccharidosis II, Mucopolysaccharidosis III-A, Mucopolysaccharidosis Type IIIA, Parkinson Disease

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for DNLI.

SEC EDGAR Filings

All SEC filings for Denali Therapeutics Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.